Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV
Abstract Hepatic steatosis (HS) related to nonalcoholic fatty liver disease (NAFLD) is increasing globally. In people living with human immunodeficiency virus (PLWH) risk factors of HS are increased. The impact of HS on outcomes and in particular health‐related quality of life (HRQL) in PLWH remains...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2022-08-01
|
| Series: | Hepatology Communications |
| Online Access: | https://doi.org/10.1002/hep4.1958 |
| _version_ | 1827881104945709056 |
|---|---|
| author | Maurice Michel Christian Labenz Malena Anders Alisha Wahl Lisann Girolstein Leonard Kaps Wolfgang M. Kremer Yvonne Huber Peter R. Galle Martin Sprinzl Jörn M. Schattenberg |
| author_facet | Maurice Michel Christian Labenz Malena Anders Alisha Wahl Lisann Girolstein Leonard Kaps Wolfgang M. Kremer Yvonne Huber Peter R. Galle Martin Sprinzl Jörn M. Schattenberg |
| author_sort | Maurice Michel |
| collection | DOAJ |
| description | Abstract Hepatic steatosis (HS) related to nonalcoholic fatty liver disease (NAFLD) is increasing globally. In people living with human immunodeficiency virus (PLWH) risk factors of HS are increased. The impact of HS on outcomes and in particular health‐related quality of life (HRQL) in PLWH remains unknown. The aim of this cross‐sectional cohort study (FLASH, Prevalence of Advanced Fibrosis in Patients Living With HIV) was to determine the contribution of HS on HRQL in PLWH and to identify confounders on HRQL. A total of 245 PLWH were prospectively enrolled. HS was assessed using vibration‐controlled transient elastography and defined as a controlled attenuation parameter (CAP) of ≥ 275 dB/m. The analysis was performed between CAP < 275 and ≥ 275 dB/m. The generic European Quality‐of‐Life 5‐Dimension 5‐Level questionnaire was used to determine differences in the HRQL. Univariable and multivariable linear regression models were applied to identify predictors with impaired HRQL in both groups. In this cohort, 65% (n = 160) presented without and 35% (n = 85) with HS, of whom most had NAFLD (n = 65, 76.5%). The HRQL (UI‐value) was significantly lower in PLWH and steatosis (0.86 ± 0.18) in comparison with no steatosis (0.92 ± 0.13). Unemployment (p = 0.025) and waist circumference (p = 0.017) remained independent predictors of a poor HRQL in the steatosis subgroup. In turn, age (p = 0.045), female sex (p = 0.030), body mass index (p = 0.010), and arterial hypertension (p = 0.025) were independent predictors of a low HRQL in the subgroup without steatosis. Conclusion: HS and metabolic comorbidities negatively affect the HRQL. Addressing these factors may improve patient‐reported and liver‐related outcomes in PLWH. |
| first_indexed | 2024-03-12T18:33:10Z |
| format | Article |
| id | doaj.art-abd4c70e3c16460b838335e05984d99c |
| institution | Directory Open Access Journal |
| issn | 2471-254X |
| language | English |
| last_indexed | 2024-03-12T18:33:10Z |
| publishDate | 2022-08-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Hepatology Communications |
| spelling | doaj.art-abd4c70e3c16460b838335e05984d99c2023-08-02T08:12:18ZengWolters Kluwer Health/LWWHepatology Communications2471-254X2022-08-01682011202110.1002/hep4.1958Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIVMaurice Michel0Christian Labenz1Malena Anders2Alisha Wahl3Lisann Girolstein4Leonard Kaps5Wolfgang M. Kremer6Yvonne Huber7Peter R. Galle8Martin Sprinzl9Jörn M. Schattenberg10Metabolic Liver Disease Research Program, I. Department of Medicine University Medical Center of the Johannes Gutenberg‐University Mainz GermanyMetabolic Liver Disease Research Program, I. Department of Medicine University Medical Center of the Johannes Gutenberg‐University Mainz GermanyMetabolic Liver Disease Research Program, I. Department of Medicine University Medical Center of the Johannes Gutenberg‐University Mainz GermanyMetabolic Liver Disease Research Program, I. Department of Medicine University Medical Center of the Johannes Gutenberg‐University Mainz GermanyMetabolic Liver Disease Research Program, I. Department of Medicine University Medical Center of the Johannes Gutenberg‐University Mainz GermanyMetabolic Liver Disease Research Program, I. Department of Medicine University Medical Center of the Johannes Gutenberg‐University Mainz GermanyMetabolic Liver Disease Research Program, I. Department of Medicine University Medical Center of the Johannes Gutenberg‐University Mainz GermanyMetabolic Liver Disease Research Program, I. Department of Medicine University Medical Center of the Johannes Gutenberg‐University Mainz GermanyMetabolic Liver Disease Research Program, I. Department of Medicine University Medical Center of the Johannes Gutenberg‐University Mainz GermanyMetabolic Liver Disease Research Program, I. Department of Medicine University Medical Center of the Johannes Gutenberg‐University Mainz GermanyMetabolic Liver Disease Research Program, I. Department of Medicine University Medical Center of the Johannes Gutenberg‐University Mainz GermanyAbstract Hepatic steatosis (HS) related to nonalcoholic fatty liver disease (NAFLD) is increasing globally. In people living with human immunodeficiency virus (PLWH) risk factors of HS are increased. The impact of HS on outcomes and in particular health‐related quality of life (HRQL) in PLWH remains unknown. The aim of this cross‐sectional cohort study (FLASH, Prevalence of Advanced Fibrosis in Patients Living With HIV) was to determine the contribution of HS on HRQL in PLWH and to identify confounders on HRQL. A total of 245 PLWH were prospectively enrolled. HS was assessed using vibration‐controlled transient elastography and defined as a controlled attenuation parameter (CAP) of ≥ 275 dB/m. The analysis was performed between CAP < 275 and ≥ 275 dB/m. The generic European Quality‐of‐Life 5‐Dimension 5‐Level questionnaire was used to determine differences in the HRQL. Univariable and multivariable linear regression models were applied to identify predictors with impaired HRQL in both groups. In this cohort, 65% (n = 160) presented without and 35% (n = 85) with HS, of whom most had NAFLD (n = 65, 76.5%). The HRQL (UI‐value) was significantly lower in PLWH and steatosis (0.86 ± 0.18) in comparison with no steatosis (0.92 ± 0.13). Unemployment (p = 0.025) and waist circumference (p = 0.017) remained independent predictors of a poor HRQL in the steatosis subgroup. In turn, age (p = 0.045), female sex (p = 0.030), body mass index (p = 0.010), and arterial hypertension (p = 0.025) were independent predictors of a low HRQL in the subgroup without steatosis. Conclusion: HS and metabolic comorbidities negatively affect the HRQL. Addressing these factors may improve patient‐reported and liver‐related outcomes in PLWH.https://doi.org/10.1002/hep4.1958 |
| spellingShingle | Maurice Michel Christian Labenz Malena Anders Alisha Wahl Lisann Girolstein Leonard Kaps Wolfgang M. Kremer Yvonne Huber Peter R. Galle Martin Sprinzl Jörn M. Schattenberg Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV Hepatology Communications |
| title | Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV |
| title_full | Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV |
| title_fullStr | Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV |
| title_full_unstemmed | Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV |
| title_short | Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV |
| title_sort | effect of hepatic steatosis and associated metabolic comorbidities on health related quality of life in people living with hiv |
| url | https://doi.org/10.1002/hep4.1958 |
| work_keys_str_mv | AT mauricemichel effectofhepaticsteatosisandassociatedmetaboliccomorbiditiesonhealthrelatedqualityoflifeinpeoplelivingwithhiv AT christianlabenz effectofhepaticsteatosisandassociatedmetaboliccomorbiditiesonhealthrelatedqualityoflifeinpeoplelivingwithhiv AT malenaanders effectofhepaticsteatosisandassociatedmetaboliccomorbiditiesonhealthrelatedqualityoflifeinpeoplelivingwithhiv AT alishawahl effectofhepaticsteatosisandassociatedmetaboliccomorbiditiesonhealthrelatedqualityoflifeinpeoplelivingwithhiv AT lisanngirolstein effectofhepaticsteatosisandassociatedmetaboliccomorbiditiesonhealthrelatedqualityoflifeinpeoplelivingwithhiv AT leonardkaps effectofhepaticsteatosisandassociatedmetaboliccomorbiditiesonhealthrelatedqualityoflifeinpeoplelivingwithhiv AT wolfgangmkremer effectofhepaticsteatosisandassociatedmetaboliccomorbiditiesonhealthrelatedqualityoflifeinpeoplelivingwithhiv AT yvonnehuber effectofhepaticsteatosisandassociatedmetaboliccomorbiditiesonhealthrelatedqualityoflifeinpeoplelivingwithhiv AT peterrgalle effectofhepaticsteatosisandassociatedmetaboliccomorbiditiesonhealthrelatedqualityoflifeinpeoplelivingwithhiv AT martinsprinzl effectofhepaticsteatosisandassociatedmetaboliccomorbiditiesonhealthrelatedqualityoflifeinpeoplelivingwithhiv AT jornmschattenberg effectofhepaticsteatosisandassociatedmetaboliccomorbiditiesonhealthrelatedqualityoflifeinpeoplelivingwithhiv |